Ann: Temporary pause in new enrolments for LAVENDER trial in US, page-77

Newron updates its shareholders and collects full trust from the shareholders. Same termination decision for the rett study for covid 19, but the title earns 16%. Evidently NEU was manipulated down to the level of 1 dollar for interests unrelated to experimentation. For a change of pace on the market, it will be necessary to wait for the annual meeting with shareholders scheduled for this month.

Newron Pharmaceuticals SpA ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of new therapies for patients with diseases of the central and peripheral nervous system, has announced that its shareholders have approved all movements on the agenda of the Board of Directors of 2020. The motions consisted in the approval of the Company's financial statements as at 31 December 2019 and in the appointment of all members of the Board of Directors. Today Newron also provides an update of its clinical, commercial and operational activities, in light of the recent COVID-19 pandemic. The health and safety of patients, healthcare professionals and our employees is paramount and Newron has taken proactive measures in response to the COVID-19 situation to protect all stakeholders and ensure business continuity. This pandemic led to the prioritization of all hospital staff available to provide COVID-19 patient care over research studies, a decision that Newron fully supports as ethically and socially responsible. However, this decision means that the Company therefore anticipates a delay in starting its planned studies with Evenamide in schizophrenia. The Company cannot predict how long the COVID-19 pandemic will delay the start of its clinical trials, but will continue to work to prepare the studies for the start as soon as it is safe and practical to do so. As for Newron's Sarizotan Treatment of Apneas in Rett Syndrome (STARS) clinical trial, the study was completed in December 2019 and the clinical database for the STARS trial remains locked and blind. Following the meeting with the United States Food and Drug Administration, the company continues to expect to share its top results with the global Rett community and the financial community in the second quarter of 2020. Newron has established channels to enable patients to open-label extension of STARS to study uninterrupted access to the drugs on which they depend. Newron will update the market with any material developments, as appropriate